Black Diamond Therapeutics, Inc. Cash Flow Statement
BDTX|2 years of annual SEC 10-K data (FY2019-FY2020)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$52M
FY2020
Free Cash Flow
-$52M
FY2020
Capital Expenditures
$142,000
Cash used for long-term assets
Dividends Paid
N/A
FY2020
Black Diamond Therapeutics, Inc. used $52M in operating cash flow and negative free cash flow of $52M in FY2020.
Based on SEC 10-K filings.
Key Data Points
- Piotroski F-Score: 2/9 criteria passed
- Altman Z-Score 5.60 (safe zone, above 2.9 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -21.9% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 |
|---|---|---|
| Net Income | -$67.3M | -$35.3M |
| Operating Cash Flow | -$52.1M | -$24.7M |
| Capital Expenditures | $142.0K | $21.0K |
| Free Cash Flow | -$52.3M | -$24.7M |